and as Vice President, Treasurer. Ms. Falberg currently serves
on the boards of public companies, including Arcus Biosciences,
Inc., Nuvation Bio, Urogen Pharma Ltd., and The Trade Desk, Inc.
Ms. Falberg previously served on the boards of directors of
Aimmune Therapeutics, Axovant Sciences, Ltd., BioMarin
Pharmaceutical Inc., Medivation Inc., Halozyme Therapeutics, Inc.,
aTyr Pharma, Inc., and multiple other companies. Ms. Falberg
is an inactive certified public accountant. Ms. Falberg holds
an M.B.A. in Finance and B.A. in Economics from the University of
California, Los Angeles.
We believe Ms. Falberg is qualified to serve on our board of
directors due to her extensive background in the life science
industry and her leadership experience as a senior financial
executive, director and audit committee member of various other
companies in the life science industry.
Dr. Gerrit Klaerner, Ph.D., our
founder, has served as a member of our board of directors since
July 2013 and as our Chief
Executive Officer and President since August 2013. Dr. Klaerner was
a founder of Relypsa, Inc. and served as its President and as a member
of its board of directors from October 2007 until June 2013.
Dr. Klaerner co-founded
Ilypsa, Inc. in 2003 and served as its Chief Business Officer and
Senior Vice President from
December 2006 until July 2007 and its Director of Technology
Assessment and Business Development from January 2003 until December 2006. Dr.
Klaerner served in Symyx Technologies, Inc. from October 1998
until January 2003 as
Staff Scientist, Senior Staff Scientist and Director of Business
Development. Dr. Klaerner received his Ph.D. in polymer and organic
chemistry from the Max Planck Institute for Polymer Research
in Mainz, Germany, his
M.S. in Chemistry from the Philipps University of Marburg and
completed post-doctoral research at Stanford University and the IBM
Almaden Research Center.
We believe that Dr. Klaerner is qualified to serve as our President
and Chief Executive Officer and on our board of directors due to
his extensive experience in leadership and management roles at
various life sciences companies.
Dr. Klaus R. Veitinger, M.D., Ph.D., M.B.A., has served as a member of our board of
directors since February
2014 and as our Chairman of the Board since September 2015. Dr.
Veitinger has served as a Venture Partner with OrbiMed Advisors LLC, an
affiliate of one of our principal stockholders, since October 2007.
Prior to OrbiMed Advisors,
Dr. Veitinger was a Member of the Executive Board of Schwarz Pharma
AG and the Chief Executive
Officer of Schwarz Pharma, Inc. with responsibility for the U.S.
and Asia businesses. Dr. Veitinger has served on the boards of public companies,
including Intercept Pharmaceuticals, Inc. from August 2012
until July 2016 and
Relypsa, Inc. from October 2010 until June 2015, and currently
serves on the board of scPharmaceuticals, Inc. since November 2017.
Dr. Veitinger currently serves on the boards of directors of
the following private
companies: Neurogastrx, Inc. and Promentis Pharmaceuticals, Inc.
For seven years he was a Director of PhRMA. Dr. Veitinger received his
M.D. and his Ph.D. from the University of Heidelberg. He
earned his M.B.A. at
INSEAD in France.
We believe that Dr. Veitinger is qualified to serve on our board of
directors due to his management and investment experience in the
life sciences sector and medical and scientific background.
Continuing Directors – Class I Directors
Dr. Sandra I. Coufal, M.D., has
served as a member of our board of directors since July 2013 and as
a member of our Scientific
Advisory Board since August 2013. Dr. Coufal is a co-founder and
has served as a co-manager
of Sibling Capital Ventures LLC, an affiliate of one of our
principal stockholders, since 2013. Dr. Coufal was a co-founder and a
co-manager of Sibling Capital, LLC from 2012 to 2016. For the
past 19 years, Dr.
Coufal has been the Biomedical Advisor for the Genomics Institute
of the Novartis Research Foundation. Dr. Coufal served as the Head of
the Division of Internal Medicine at the Torrey Pines site
of Scripps Clinic from
1997 until 1999, and was a member of the board of directors of
Scripps Green Hospital from 1997 until 1999. Dr. Coufal founded and
served on Relypsa, Inc.’s Scientific Advisory Board since 2007 and
was a co-founder of
Ilypsa’s Scientific Advisory Board. Dr. Coufal has served on the
boards of directors of BioAesthetics Corporation and SafetySpot Inc.
since February 2016 and March 2017, respectively. On a
volunteer basis, Dr. Coufal has
served on the Advisory Board of the New Orleans BioFund since 2017.
She has also served in a
volunteer capacity on the Advisory Board of The Vision of Children
Foundation since 2017. Dr. Coufal has been a Member of the
Advisory Board of the Rancho Santa Fe Women’s Fund since
2015, serving as its
Advisory Chair from 2016-2018. Dr. Coufal served as Associate
Faculty in the Division of Internal Medicine for the University of California,
San Diego, unsalaried. She completed an internship and residency
in Internal Medicine at
the University of Texas Southwestern Medical School at Dallas. Dr.
Coufal received her